Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway

Figures & data

Table 1. Patient characteristics: distribution of age, T stage and cause of death, by gender and in total in the underlying study population.

	Men	Women	All
%	76	24	100
Age at diagnosis (years),median [10–90%]	73 [57–85]	74 [56–87]	73 [57–85]
T stage (%)
Ta G1G2	41	42	41
Ta G3	9	7	9
Tis	1	1	1
T1	16	14	16
T2–4 (muscle-invasive)	33	36	34
Death (%)
UCB	20	24	21
Other cancer	11	9	11
Other than cancer	19	17	19
Unknown	4	3	3
Alive	45	48	46

UCB: urothelial carcinoma of the urinary bladder.

Figure 1. Estimated crude probabilities of death due to urothelial carcinoma of the urinary bladder (UCB) (dark gray) and due to other causes (light gray) for up to 10 years after diagnosis for any combination of gender (A: male; B: female), age (57, 73 or 85 years) and T stage (TaG1G2, TaG3, Tis, T1, T2–4).

Table 2. Crude probabilities of death due to UCB (including confidence intervals) for patients with urothelial carcinoma of the urinary bladder.

	Men							Women
Time sincediagnosis	T stage	Age 57 years		Age 73 years		Age 85 years		T stage	Age 57 years		Age 73 years		Age 85 years
1 year	TaG1G2	0.01	(0.01, 0.02)	0.02	(0.01, 0.02)	0.02	(0.02, 0.03)	TaG1G2	0.01	(0.01, 0.02)	0.02	(0.02, 0.03)	0.03	(0.02, 0.04)
	TaG3	0.02	(0.02, 0.03)	0.03	(0.02, 0.05)	0.05	(0.04, 0.07)	TaG3	0.03	(0.02, 0.04)	0.05	(0.03, 0.06)	0.07	(0.05, 0.10)
	Tis	0.03	(0.01, 0.05)	0.05	(0.02, 0.08)	0.07	(0.02, 0.12)	Tis	0.04	(0.01, 0.07)	0.07	(0.02, 0.11)	0.10	(0.03, 0.17)
	T1	0.05	(0.04, 0.06)	0.07	(0.06, 0.08)	0.11	(0.09, 0.13)	T1	0.07	(0.05, 0.08)	0.10	(0.08, 0.12)	0.15	(0.13, 0.18)
	T2–4	0.18	(0.16, 0.20)	0.27	(0.25, 0.29)	0.38	(0.35, 0.41)	T2-4	0.25	(0.22, 0.28)	0.36	(0.32, 0.39)	0.50	(0.46, 0.54)
5 years	TaG1G2	0.03	(0.02, 0.03)	0.04	(0.03, 0.05)	0.05	(0.04, 0.07)	TaG1G2	0.03	(0.02, 0.04)	0.05	(0.03, 0.06)	0.07	(0.05, 0.09)
	TaG3	0.06	(0.04, 0.08)	0.09	(0.06, 0.11)	0.11	(0.08, 0.15)	TaG3	0.07	(0.05, 0.09)	0.10	(0.07, 0.14)	0.15	(0.10, 0.19)
	Tis	0.08	(0.03, 0.14)	0.12	(0.04, 0.20)	0.16	(0.06, 0.26)	Tis	0.10	(0.03, 0.16)	0.14	(0.05, 0.23)	0.20	(0.08, 0.32)
	T1	0.12	(0.10, 0.14)	0.18	(0.15, 0.20)	0.23	(0.20, 0.26)	T1	0.14	(0.12, 0.17)	0.21	(0.18, 0.24)	0.29	(0.25, 0.33)
	T2–4	0.42	(0.39, 0.46)	0.55	(0.53, 0.58)	0.64	(0.61, 0.67)	T2–4	0.48	(0.43, 0.52)	0.63	(0.59, 0.66)	0.74	(0.71, 0.77)
10 years	TaG1G2	0.03	(0.02, 0.04)	0.05	(0.03, 0.06)	0.06	(0.04, 0.07)	TaG1G2	0.04	(0.03, 0.05)	0.05	(0.04, 0.07)	0.07	(0.05, 0.09)
	TaG3	0.07	(0.05, 0.09)	0.10	(0.07, 0.13)	0.12	(0.08, 0.16)	TaG3	0.08	(0.05, 0.10)	0.11	(0.08, 0.15)	0.15	(0.11, 0.20)
	Tis	0.09	(0.03, 0.16)	0.13	(0.05, 0.22)	0.17	(0.06, 0.27)	Tis	0.11	(0.04, 0.18)	0.16	(0.06, 0.26)	0.21	(0.08, 0.34)
	T1	0.14	(0.12, 0.16)	0.20	(0.17, 0.23)	0.24	(0.21, 0.28)	T1	0.16	(0.13, 0.19)	0.23	(0.19, 0.27)	0.30	(0.26, 0.35)
	T2–4	0.47	(0.43, 0.51)	0.60	(0.57, 0.63)	0.66	(0.63, 0.69)	T2–4	0.52	(0.47, 0.57)	0.66	(0.62, 0.71)	0.76	(0.72, 0.79)

The respective estimators are shown for all combinations of age (57, 73 and 85 years), years since diagnosis (1, 5 and 10 years) and T stage (TaG1G2, TaG3, Tis, T1 and T2–4).

Figure 2. Loss in expectation of lifetime dependent on age, gender and T stage.

Table 3. Estimated loss in expectation of lifetime including confidence intervals (in parentheses), by age, gender and T stage.

	Loss of life expectancy
	T stage	Age 57 years		Age 73 years		Age 85 years
Men	TaG1G2	0.8	(0.6, 1.1)	0.5	(0.4, 0.7)	0.3	(0.2, 0.4)
	TaG3	2.0	(1.4, 2.6)	1.3	(0.9, 1.6)	0.7	(0.5, 1.0)
	Tis	2.4	(0.8, 3.9)	1.5	(0.6, 2.5)	0.9	(0.3, 1.5)
	T1	3.6	(3.0, 4.3)	2.1	(1.8, 2.4)	1.2	(1.0, 1.4)
	T2–4	12.4	(11.3, 13.6)	7.3	(6.9, 7.6)	3.7	(3.6, 3.9)
Women	TaG1G2	1.0	(0.7, 1.4)	0.7	(0.5, 1.0)	0.5	(0.3, 0.6)
	TaG3	2.2	(1.4, 3.0)	1.8	(1.2, 2.3)	0.9	(0.6, 1.2)
	Tis	3.0	(1.0, 5.0)	2.1	(0.8, 3.4)	1.4	(0.6, 2.3)
	T1	4.6	(3.6, 5.6)	3.3	(2.7, 3.8)	1.9	(1.6, 2.1)
	T2–4	15.2	(13.4, 17.0)	9.6	(9.0, 10.3)	5.2	(4.9, 5.4)